Market Overview

UPDATE: Bank of America Upgrades Myriad Genetics to Buy on Diversification Strategy

Share:
Related MYGN
Barclays Explains Its Bullish Call On Myriad Genetics
Myriad Gets $200 Million More For Share Repurchase Program

Bank of America raised its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy and increased its price objective from $30 to $32.

Bank of America commented, "We upgrade MYGN shares to Buy from Neutral, as we are more positive on the company's efforts to diversify the business and expand its addressable markets, particularly as the company's flagship product, BRACAnalysis, matures. We think MYGN's strategy to increase its penetration in certain cancer indications while expanding overseas is viable, and are more optimistic on the ability to protect the BRACAnalysis franchise. We are also incrementally more positive on Prolaris and the pipeline, as well as the company's efforts in companion diagnostics."

Myriad Genetics closed at $25.37 on Tuesday.

Latest Ratings for MYGN

DateFirmActionFromTo
Jul 2016Bank of AmericaDowngradesNeutralUnderperform
May 2016Avondale PartnersMaintainsMarket Outperform
May 2016Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!